A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The division cycle of eukaryotic cells is regulated by a family of protein kinases known as the cyclin-dependent kinases (CDKs). The sequential activation of individual members of this family and their consequent phosphorylation of critical substrates promotes orderly progression through the cell cycle. The complexes formed by CDK4 and the D-type cyclins have been strongly implicated in the control of cell proliferation during the G1 phase. CDK4 exists, in part, as a multi-protein complex with a D-type cyclin, proliferating cell nuclear antigen and a protein, p21 (refs 7-9). CDK4 associates separately with a protein of M(r) 16K, particularly in cells lacking a functional retinoblastoma protein. Here we report the isolation of a human p16 complementary DNA and demonstrate that p16 binds to CDK4 and inhibits the catalytic activity of the CDK4/cyclin D enzymes. p16 seems to act in a regulatory feedback circuit with CDK4, D-type cyclins and retinoblastoma protein.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p16, on the other hand, acts through the Retinoblastoma (Rb) pathway (Serrano et al, 1993).”
From Distinct senotypes in p16- and p21-positive cells across human and mouse aging tissues (2025) · cites this paper as Serrano et al, 1993
In the citing paper
“p16INK4A is a 16 KDa protein that directly binds to CDK4/6 and blocks the formation of cyclinD-CDK4/6 complexes, thereby preventing phosphorylation of RB and promoting expression of E2F target genes (Serrano et al., 1993).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Serrano et al., 1993
In the citing paper
“This member of the INK4a family is a cyclin D-dependent kinase CDK4 and CDK6 inhibitor, which prevents the phosphorylation of the retinoblastoma protein (Rb), therefore leading to suspension of the cell cycle before the S-phase [78,79].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [78]
In the citing paper
“Currently, p16Ink4a is one of the widely used markers for studying cellular senescence, and it plays a prominent role in inhibiting CDK4/6 and restricting the progression of G1 to S phase in the cell cycle.16,17”
From Identifying specific functional roles for senescence across cell types (2024) · doi:10.1016/j.cell.2024.09.021 · cites this paper as [16]
In the citing paper
“Currently, p16Ink4a is one of the widely used markers for studying cellular senescence, and it plays a prominent role in inhibiting CDK4/6 and restricting the progression of G1 to S phase in the cell cycle.16,17”
From Identifying specific functional roles for senescence across cell types (2024) · doi:10.1016/j.cell.2024.09.021 · cites this paper as [16]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antibodies, a laboratory manual
(1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90130-3 · Cited by 12,366
A novel genetic system to detect protein–protein interactions
Fields, S., & Song, O.-K. (1989) · Nature · doi:10.1038/340245a0 · Cited by 6,114
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Self-citationSherr, C. J. (1993) · Cell · doi:10.1016/0092-8674(93)90636-5 · Cited by 1,960
(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264
Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle
Matsushime, H., Roussel, M. F., Ashmun, R. A., & Sherr, C. J. (1991) · Cell · doi:10.1016/0092-8674(91)90101-4 · Cited by 1,167
Xiong, Y., Zhang, H., & Beach, D. (1992) · Cell · doi:10.1016/0092-8674(92)90518-h · Cited by 1,021
Self-citationFunctional interactions of the retinoblastoma protein with mammalian D-type cyclins
Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010
A family of human cdc2-related protein kinases.
Meyerson, M., Enders, G. H., Wu, C. L., Su, L. K., Gorka, C., Nelson, C., Harlow, E., & Tsai, L. H. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05360.x · Cited by 923
Matsushime, H., Ewen, M. E., Strom, D. K., Kato, J.-Y., Hanks, S. K., Roussel, M. F., & Sherr, C. J. (1992) · Cell · doi:10.1016/0092-8674(92)90360-o · Cited by 897
Research works printed but not linked: 2
- Motokura, T. & Arnold, A. Biochim. biophys. Acta 1155, 63–78 (1993).
- Lukas, J., Pagano, M., Staskova, Z., Draetta, G. & Bartek, J. Oncogene (in the press).
Cited by
Items 901–1,000 of 1,022
Overexpression of Cyclin‐dependent Kinase‐activating CDC25B Phosphatase in Human Gastric Carcinomas
Kudo, Y., Yasui, W., Ue, T., Yamamoto, S., Yokozaki, H., Nikai, H., & Tahara, E. (1997) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1997.tb00313.x · Cited by 91
2,6,9-trisubstituted purines : Optimization towards highly potent and selective CDK1 inhibitors
Imbach, P. A., Capraro, H., Furet, P., Mett, H., Meyer, T., & Zimmermann, J. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00691-x · Cited by 83
Odze, R. D., Brown, C. A., Hartmann, C. J., Noffsinger, A. E., & Fogt, F. (2000) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200009000-00003 · Cited by 83
“and, as such, represents a key regulator in the progression of cells through the G1 phase of the cell cycle.(10,25)”
BackgroundNairn, R. S., Kazianis, S., McEntire, B. B., Della Coletta, L., Walter, R. B., & Morizot, D. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.23.13042 · Cited by 83
A Single Genetic Origin for the G101W CDKN2A Mutation in 20 Melanoma-Prone Families
Ciotti, P., Struewing, J. P., Mantelli, M., Chompret, A., Avril, M., Santi, P. L., Tucker, M. A., Bianchi‐Scarrà, G., Paillerets, B. B., & Goldstein, A. M. (2000) · The American Journal of Human Genetics · doi:10.1086/303001 · Cited by 83
“Therefore p16, the first melanoma-susceptibility gene to have been identified, negatively regulates progression through G1 into S phase of the cell cycle (Serrano et al. 1993, 1995).”
BackgroundA direct effect of activated human p53 on nuclear DNA replication.
Cox, L. S., Hupp, T. R., Midgley, C., & Lane, D. P. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07201.x · Cited by 90
Cellular Senescence and Vascular Disease: Novel Routes to Better Understanding and Therapy
Yin, H., & Pickering, J. G. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.02.051 · Cited by 82
Knudsen, E. S., Kumarasamy, V., Chung, S., Ruiz, A., Vail, P., Tzetzo, S., Wu, J., Nambiar, R., Sivinski, J., Chauhan, S. S., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-321000 · Cited by 82
“13 Interestingly, in preclinical studies, PDAC models are surprisingly resistant to CDK4/6 inhibition.”
Zhang, A., Feng, H., Yang, G., Pan, X., Jiang, X., Huang, X., Dong, X.-X., Da-ping, Y., Xie, Y., Luo, P., et al. (2007) · Environmental Health Perspectives · doi:10.1289/ehp.9272 · Cited by 83
Procyanidin B2 has anti- and pro-oxidant effects on metal-mediated DNA damage
Sakano, K., Mizutani, M., Murata, M., Oikawa, S., Hiraku, Y., & Kawanishi, S. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.05.024 · Cited by 84
Shimamoto, T., Ohyashiki, J. H., & Ohyashiki, K. (2005) · Leukemia Research · doi:10.1016/j.leukres.2004.11.014 · Cited by 90
Molecular Genetics of Head and Neck Cancer
Gleich, L. L., & Salamone, F. N. (2002) · Cancer Control · doi:10.1177/107327480200900502 · Cited by 97
Olopade, O. I., Pomykala, H. M., Hagos, F., Sveen, L. W., Espinosa, R., Dreyling, M. H., Gursky, S., Stadler, W. M., Le Beau, M. M., & Bohlander, S. K. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6489 · Cited by 82
Mirzayans, R., Andrais, B., Hansen, G., & Murray, D. (2012) · Biochemistry Research International · doi:10.1155/2012/951574 · Cited by 81
“The p16 protein was discovered in the early 1990s, and was extensively studied for its ability to influence cell progression from G1 to S phase. p16 was shown to inhibit the kinase activities of the cyclin D-dependent kinases CDK4 [28] and CDK6 [29].”
BackgroundInfluentialInhibition of proliferation of MCF-7 breast cancer cells by a blocker of Ca2+-permeable channel
Nie, L., Oishi, Y., Doi, I., Shibata, H., & Kojima, I. (1997) · Cell Calcium · doi:10.1016/s0143-4160(97)90107-x · Cited by 81
Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas
Yoshino, A., Katayama, Y., Ogino, A., Watanabe, T., Yachi, K., Ohta, T., Komine, C., Yokoyama, T., & Fukushima, T. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9316-9 · Cited by 87
“related with passage through the G1 checkpoint [4, 5].”
BackgroundA common variant of CDKN2A (p16) predisposes to breast cancer: Table 1
Dębniak, T., Górski, B., Huzarski, T., Byrski, T., Cybulski, C., Mackiewicz, A., Gozdecka-Grodecka, S., Gronwald, J., Kowalska, E., Haus, O., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.031476 · Cited by 92
Perrone, F., Tabano, S. M., Colombo, F., Dagrada, G. P., Birindelli, S., Gronchi, A., Colecchia, M., Pierotti, M. A., & Pilotti, S. (2003) · PubMed · Cited by 87
p12DOC-1 Is a Novel Cyclin-Dependent Kinase 2-Associated Protein
Shintani, S., Ohyama, H., Zhang, X., McBride, J., Matsuo, K., Tsuji, T., Hu, M. G., Hu, G., Kohno, Y., Lerman, M. I., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/.20.17.6300-6307.2000 · Cited by 83
Venkatesh, D., Fredette, N., Rostama, B., Tang, Y., Vary, C. P. H., Liaw, L., & Urs, S. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.221945 · Cited by 81
Genetic and Molecular Markers of Urothelial Premalignancy and Malignancy
Cordon‐Cardo, C., Côté, R. J., & Sauter, G. (2000) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/003655900750169338 · Cited by 83
The INK4A/ARF Locus: Role in Cell Cycle Control and Apoptosis and Implications for Glioma Growth
Ivanchuk, S. M., Mondal, S., Dirks, P. B., & Rutka, J. T. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1010632309113 · Cited by 93
“Simultaneously, p16 (p16) was identified in a yeast two hybrid screen for proteins interacting with cyclin dependent kinase-4 (CDK4) as bait [4].”
BackgroundMiyake, H., Suzuki, T., Hirai, H., & Yoshida, M. (1999) · Virology · doi:10.1006/viro.1998.9500 · Cited by 92
Peters, G. G. (1994) · Nature · doi:10.1038/371204a0 · Cited by 88
Chen, Y., Paliwal, S., Draheim, K., Grossman, S. R., & Lewis, B. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1960 · Cited by 86
“D/cdk4, p16 maintains pRb in the hypophosphorylated state and regulates the G1 transition of the cell cycle ( 13 ).”
BackgroundHuman papillomavirus in high- and low-risk areas of oesophageal squamous cell carcinoma in China
Shuyama, K., Castillo, A., Aguayo, F., Sun, Q., Khan, N., Koriyama, C., & Akiba, S. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603765 · Cited by 79
“Note, however, that p16INK4a is frequently inactivated through hypermethylation of p16INK4a promoter and through deletion at near-p16 loci (Serrano et al, 1993; Xing et al, 1999; Tokunaga et al, 2002).”
BackgroundResultHenshall, S. M., Quinn, D. I., Lee, C. S., Head, D. R., Golovsky, D., Brenner, P. C., Delprado, W., Stricker, P. D., Grygiel, J. J., & Sutherland, R. L. (2001) · Macquarie University · Cited by 90
Expressing patterns of p16 and CDK4 correlated to prognosis in colorectal carcinoma
Zhao, P., Hu, Y.-C., & Talbot, I. C. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i10.2202 · Cited by 83
Al-Mulla, F., Keith, W. N., Pickford, I. R., Going, J. J., & Birnie, G. D. (1999) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199904)24:4<306::aid-gcc3>3.0.co;2-5 · Cited by 133
Chaubert, P., Gayer, R., Zimmermann, A., Fontolliet, C., Stamm, B., Bosman, F. T., & Shaw, P. H. (1997) · Hepatology · doi:10.1002/hep.510250613 · Cited by 88
The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer.
Kusume, T., Tsuda, H., Kawabata, M., Inoue, T., Umesaki, N., Suzuki, T., & YAMAMOTO, K. (1999) · PubMed · Cited by 80
Puig, S., Ruiz, A., Lázaro, C., CASTEL, T., Lynch, M., Palou, J., Vilalta, A., Weissenbach, J., Mascaró, J. M., & Estivill, X. (1995) · Europe PMC (PubMed Central) · Cited by 95
Genetic analysis of cellular senescence
Vojta, P. J., & Barrett, J. C. (1995) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00002-w · Cited by 95
Ferrando, A., Balbín, M., Pendás, A. M., Vizoso, F. J., Velasco, G., & López-Otín, C. (1996) · Human Genetics · doi:10.1007/bf00218840 · Cited by 86
“At present, five of these proteins have been characterized at the amino acid sequence level, including p21 (E1-Deiry et al. 1993; Xiong et al. 1993; Harper et al. 1993; Gu et al. 1993), pl6 ( Serrano et al. 1993 ), p27 (Polyak et al. 1994a; Toyoshima and Hunter 1994), p15 (Hannon and Beach 1994) and p18 (Guan et al. 1…”
BackgroundXiong, Y., Kuppuswamy, D., Li, Y., Livanos, E. M., Hixon, M., White, A., Beach, D., & Tlsty, T. D. (1996) · Journal of Virology · doi:10.1128/jvi.70.2.999-1008.1996 · Cited by 80
Self-citationDisorder-function relationships for the cell cycle regulatory proteins p21 and p27
Mitrea, D. M., Yoon, M., Li, O., & Kriwacki, R. W. (2012) · Biological Chemistry · doi:10.1515/hsz-2011-0254 · Cited by 85
“For example, phosphorylation of Thr187 by the Cdk2/cyclin E (and A) complexes (Sheaff et al. , 1997 ; Vlach et al. , 1997 ) creates a phospho-degron (Carrano et al. , 1999 ), which signals the recruitment and binding of the SCF Skp2 E3 ubiquitin ligase complex for ubiquitination and subsequent…”
Bailey, K. M., Cost, C. R., Davis, I. J., Bender, J. G., Grohar, P. J., Houghton, P. J., Isakoff, M. S., Stewart, E. S., Laack, N. N., Yustein, J. T., et al. (2019) · F1000Research · doi:10.12688/f1000research.18139.1 · Cited by 82
Mateos, M., García‐Sánz, R., López‐Pérez, R., Moro, M. J., Ocio, E. M., Hernández‐Rivas, J., Megido, M., Caballero, M. D., Fernández‐Calvo, J., Bárez, A., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03749.x · Cited by 86
“This gene is located on chromosome 9p21 in humans and it is composed of three exons, which encode a 156-amino-acid product (Serrano et al, 1993; Stone et al, 1995).”
BackgroundOncogene-Induced Senescence Does Not Require the p16INK4a or p14ARF Melanoma Tumor Suppressors
Haferkamp, S., Scurr, L. L., Becker, T. M., Frausto, M., Kefford, R. F., & Rizos, H. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.5 · Cited by 92
Neurofibromin, a Tumor Suppressor in the Nervous System
Zhu, Y., & Parada, L. F. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5138 · Cited by 93
Eom, G. H., Nam, Y. S., Oh, J. G., Choe, N., Min, H.-K., Yoo, E.-K., Kang, G., Nguyen, V. H., Min, J.-J., Kim, J.-K., et al. (2014) · Circulation Research · doi:10.1161/circresaha.114.303429 · Cited by 81
“Among those modifications, phosphorylation is well known as a critical process for enzymatic activity,(1) signal transduction by recruiting complexes,(2) DNA binding,(3) and cell division.(4) Although biological roles of other modifications, especially acetylation, have not been intensively studied yet,”
BackgroundGrønbæk, K., Brown, P. D. N., Møller, M. B., Nedergaard, T., Ralfkiaer, E. M., Mӧller, P., Zeuthen, J., & Guldberg, P. (2000) · Leukemia · doi:10.1038/sj.leu.2401901 · Cited by 86
Maloney, K. W., McGavran, L., Odom, L. F., & Hunger, S. P. (1999) · Blood · doi:10.1182/blood.v93.7.2380 · Cited by 79
Current Molecular Markers of Melanoma and Treatment Targets
Yang, K., Oak, A. S. W., Slominski, R. M., Brożyna, A. A., & Slominski, A. T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103535 · Cited by 89
Khan, A. A., Liu, X., Yan, X., Tahir, M., Ali, S., & Huang, H. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09952-0 · Cited by 83
Chin, C., Li, J., Lee, K., Huang, Y., Wang, K., Lai, H., Cheng, C., Kuo, Y., & Shi, C. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25092 · Cited by 85
“Figure 3A shows that ICI118,551 upregulated p21 and p27 expression but downregulated cyclin D1 and CDK4 expression, indicating that b2-AR blockage enhanced p21 and p27 accumulation and decreased cyclin D1/CDK4 complex formation for G1-phase arrest (Serrano et al., 1993; Toyoshima and Hunter, 1994).”
Backgroundp16 expression in primary malignant melanoma is associated with prognosis and lymph node status
Mihic‐Probst, D., Mnich, C. D., Oberholzer, P. A., Seifert, B., Sasse, B., Moch, H., & Dummer, R. (2005) · International Journal of Cancer · doi:10.1002/ijc.21608 · Cited by 85
“p16 is a negative cell-cycle regulator and normally expressed in the nucleus.(13) Three major mechanisms of p16 inactivation have been described in melanoma and head and neck carcino-”
BackgroundAn in cellulo-derived structure of PAK4 in complex with its inhibitor Inka1
Baskaran, Y., Ang, K. C., Anekal, P. V., Chan, W. L., Grimes, J. M., Manser, E., & Robinson, R. C. (2015) · Nature Communications · doi:10.1038/ncomms9681 · Cited by 80
High prevalence of p16 genetic alterations in head and neck tumours
Miracca, E. C., Kowalski, L. P., & Nagai, M. A. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690747 · Cited by 81
“p2 ina us ne s sm en an rta ran dk e ma g t a et –22, ygous et al, ous l lines cer, e , in a The oreas, ldas et 996; ediset al, ss of 9 ddi- High prevalence of p16 genetic alterations in head and neck tumours”
BackgroundInfluentialPrognostic Value of p27Kip1 and CyclinD1 Expression in Esophageal Cancer
Itami, A., Shimada, Y., Watanabe, G., & Imamura, M. (1999) · Oncology · doi:10.1159/000012067 · Cited by 81
“Seven CKIs have been identified and classified into two major families. The first family includes p16 Ink4A [”
BackgroundWianny, F., Real, F. X., Mummery, C. L., van Rooijen, M. A., Lahti, J. M., Samarut, J., & Savatier, P. (1998) · Developmental Dynamics · doi:10.1002/(sici)1097-0177(199805)212:1<49::aid-aja5>3.0.co;2-2 · Cited by 99
“Of prime importance in this process are cyclin Ds (cyclin D1, D2, or D3), which bind and activate cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), thereby phosphorylating pRb and promoting progression from mid to late G1 (Matsushime et al., 1992, 1994; Bates et al., 1994; Tam et al., 1994; Meyerson and Harlow, 1994;…”
BackgroundInfluentialCHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers
Bertoni, F., Codegoni, A. M., Furlan, D., Tibiletti, M. G., Capella, C., & Broggini, M. (1999) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199910)26:2<176::aid-gcc11>3.0.co;2-3 · Cited by 121
Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract.
Igaki, H., Sasaki, H., Tachimori, Y., Kato, H., Watanabe, H., Kimura, T., Harada, Y., Sügimura, T., & Terada, M. (1995) · PubMed · Cited by 78
Arresting developments in cell-cycle control
Pines, J. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90272-0 · Cited by 78
Application of p16/Ki-67 dual-staining cytology in cervical cancers
Yu, L., Fei, L., Liu, X., Pi, X., Wang, L., & Chen, S. (2019) · Journal of Cancer · doi:10.7150/jca.32743 · Cited by 89
p300 plays a role in p16INK4a expression and cell cycle arrest
Wang, X., Pan, L., Feng, Y., Wang, Y., Han, Q., Han, L., Han, S., Guo, J., Huang, B., & Lü, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210821 · Cited by 83
“p16INK4a (hereafter p16) has been known as a tumor suppressor gene; its product binds specifically to CDK4 and CDK6 to prevent them from interacting with cyclin D, thus inhibiting phosphorylation of the retinoblastoma protein (pRb) (Serrano et al., 1993).”
BackgroundExpression of p16 in benign and malignant cystic squamous lesions of the neck
Cao, D., Begum, S., Ali, S. Z., & Westra, W. H. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.09.006 · Cited by 77
“In HPV-positive carcinomas, transcription of the viral oncoprotein E7 functionally inactivates the retinoblastoma (Rb) gene product, causing a perturbation of key components of the Rb pathway including overexpression of the p16 tumor suppressor gene to levels that can be detected immunohistochemically [10,11].”
BackgroundWang, X., Chen, Y., Han, Q., Chan, C., Wang, H., Liu, Z., Cheng, C. H. K., Yew, D. T. W., Lin, M. C.-M., He, M., et al. (2009) · PROTEOMICS · doi:10.1002/pmic.200800155 · Cited by 80
“It functions by competing with cyclin D for the binding site of cyclin-dependent kinase-4 and preventing the associated kinase activation [36].”
BackgroundCui, C., Gan, Y., Gu, L., Wilson, J., Liu, Z., Zhang, B., & Deng, D. (2015) · Genome biology · doi:10.1186/s13059-015-0819-6 · Cited by 82
“cell growth and increased genomic instability [23, 24].”
Tong, W., Kiyokawa, H., Soos, T. J., Park, M. S., Soares, V. C., Manova, K., Pollard, J. W., & Koff, A. (1998) · PubMed · Cited by 81
Brantley, M. A., & Harbour, J. W. (2000) · PubMed · Cited by 83
Hu, Y., Watanabe, H., Ohtsubo, K., Yamaguchi, Y., Ha, A., Okai, T., & Sawabu, N. (1997) · PubMed · Cited by 77
Genetic Epidemiology of Familial Melanoma
Goldstein, A. M., & Tucker, M. A. (1995) · Dermatologic Clinics · doi:10.1016/s0733-8635(18)30066-4 · Cited by 86
CDK4 is an essential insulin effector in adipocytes
Lagarrigue, S., Lopez-Mejia, I. C., Denechaud, P.-D., Escoté, X., Castillo-Armengol, J., Jimenez, V., Chavey, C., Giralt, A., Lai, Q., Zhang, L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81480 · Cited by 76
“β Cell– specific reexpression of the Cdk4R24C allele renders CDK4 resistant to the inhibitory effects of INK4 proteins (12) and restores β cell proliferation and normoglycemic conditions (13).”
BackgroundRetractedNakanuma, Y., Sasaki, M., Sato, Y., 任香善, Ikeda, H., & Harada, K. (2009) · World Journal of Hepatology · doi:10.4254/wjh.v1.i1.35 · Cited by 84
Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL)
Hatta, Y., & Koeffler, H. (2002) · Leukemia · doi:10.1038/sj.leu.2402458 · Cited by 89
Arima, Y., Hayashi, N., Hayashi, H., Sasaki, M., Kai, K., Sugihara, E., Abe, E., Yoshida, A., Mikami, S., Nakamura, S., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26271 · Cited by 84
Polycomb group genes as epigenetic regulators of normal and leukemic hemopoiesis
Lessard, J. A., & Sauvageau, G. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00081-x · Cited by 87
Mattioli, E., Vogiatzi, P., Sun, A., Abbadessa, G., Angeloni, G., D’Ugo, D., Trani, D., Gaughan, J., Vecchio, F. M., Cevenini, G., et al. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20833 · Cited by 76
“Serrano et al. (1993) have proposed that physiological inactivation of pRb during the G1-phase leads to increased p16INK4A expression in order to limit CDK4 activity.”
BackgroundMolecular biology of laryngeal squamous cell carcinoma
Nadal, A., & Cardesa, A. (2003) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-002-0726-6 · Cited by 77
“It binds to CDK4 and prevents it from binding to cyclin D1, thus inhibiting the catalytic activity of the CDK4/Cyclin D1 complexes [ 61 ].”
BackgroundTsai, K. Y., & Tsao, H. (2004) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.30037 · Cited by 87
“S transition of the cell cycle [Serrano et al., 1993, 1995; Koh et al., 1995].”
Immunolocalization of Human p14ARF to the Granular Component of the Interphase Nucleolus
Lindström, M. S., Klangby, U., Inoue, R., Pisa, P., Wiman, K. G., & Asker, C. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4854 · Cited by 83
The Pattern of Signatures in Gastric Cancer Prognosis
Machlowska, J., Maciejewski, R., & Sitarz, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061658 · Cited by 77
“Another very important cell cycle regulatory protein is p16, which is cyclin-dependent kinase inhibitor (CDKI) [45].”
BackgroundCell senescence in neuropathology: A focus on neurodegeneration and tumours
Carreno, G., Guiho, R., & Martinez‐Barbera, J. P. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12689 · Cited by 74
Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets
Maharjan, C. K., Ear, P. H., Tran, C. G., Howe, J. R., Chandrasekharan, C., & Quelle, D. E. (2021) · Cancers · doi:10.3390/cancers13205117 · Cited by 76
“The INK4A/ARF locus encodes two different proteins, p16INK4a and p14ARF (mouse homologue p19ARF), derived from transcripts having distinct first exons but shared downstream exons that are translated in alternative reading frames [108,109].”
BackgroundInfluentialChen, M., Chen, Z.-Q., Cui, P.-G., Yao, X., Li, Y., Li, A.-S., Gong, J.-Q., & Cao, Y.-H. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08505.x · Cited by 80
Differential Roles of p16INK4A and p14ARF Genes in Prognosis of Oral Carcinoma
Sailasree, R., Abhilash, A. J. B., Sathyan, K. M., Nalinakumari, K. R., Thomas, S., & Kannan, S. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0284 · Cited by 84
“The p16 gene functions as negative regulator of the cell cycle progression through its inhibition of cdk4/6 and subsequent blockage of the cyclin-dependent phosphorylation of the Rb (4).”
BackgroundSun, Y. L., Deng, D., You, W., Bai, H., Zhang, L., Zhou, J., Shen, L., Ma, J., Xie, Y., & Li, J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0622 · Cited by 75
Faraji, F., Eisele, D. W., & Fakhry, C. (2017) · Laryngoscope Investigative Otolaryngology · doi:10.1002/lio2.37 · Cited by 78
“Rb protein degradation triggers a regulatory cascade resulting in the compensatory upregulation of another tumor suppressor, p16 (p16).(48) The mechanisms of HPV-mediated oncogenesis guide the strategies contemporary diagnostic laboratories employ to detect HPV in tumor samples.”
BackgroundBilateral Primary Uveal Melanoma
Singh, A. D., Shields, C. L., Shields, J. A., & Potter, P. D. (1996) · Ophthalmology · doi:10.1016/s0161-6420(96)30707-0 · Cited by 87
Doi, K., Ikeda, T., Itoh, H., Ueyama, K., Hosoda, K., Ogawa, Y., Yamashita, J. K., Chun, T., Inoue, M., Masatsugu, K., et al. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.21.6.930 · Cited by 75
Moller, H., & Skakkebæk, N. E. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960503)66:3<287::aid-ijc2>3.0.co;2-v · Cited by 192
Frequent In activation of CDKN2A and Rare Mutation of TP53 in PCNSL
Cobbers, J. M. J. L., Wolter, M., REIFENBERGER, J., Ring, G. U., Jessen, F., An, H., Niederacher, D., Schmidt, E., Ichimura, K., Floeth, F. W., et al. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00152.x · Cited by 82
“It acts by binding to complexes of cyclin dependent kinases (Cdk4 and Cdk6) with D-type cyclins and thereby inhibits the Cdk activation required for cell cycle progression (67, 69).”
BackgroundE2F-1 but not E2F-4 can overcome p16-induced G1 cell-cycle arrest
Mann, D. J., & Jones, N. (1996) · Current Biology · doi:10.1016/s0960-9822(02)00515-8 · Cited by 95
MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation
Jackson, M. W., Lindström, M. S., & Berberich, S. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010685200 · Cited by 74
Structural basis for chemical inhibition of CDK2
Kim, S., Schulze‐Gahmen, U., Brandsen, J., & de Azevedo, W. F. (1996) · Springer eBooks · doi:10.1007/978-1-4615-5873-6_14 · Cited by 76
Muthamil, S., Kim, H., Jang, H., Lyu, J., Shin, U. C., Go, Y., Park, S., Lee, H. G., & Park, J. H. (2024) · Advanced Biology · doi:10.1002/adbi.202400079 · Cited by 98
Gu, Z., Cao, X., Jiang, J., Li, L., Da, Z., Liu, H., & Cheng, C. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.07.012 · Cited by 77
Natarajan, E., Omobono, J. D., Guo, Z., Hopkinson, S. B., Lazar, A. J., Brenn, T., Jones, J. C. R., & Rheinwald, J. G. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.051027 · Cited by 77
“p16 is an inhibitor of the cyclin D1-dependent kinases cdk4 and cdk6.(18,19) p16 protein is not expressed during normal stratified squamous epithelial renewal or differentiation,(17,20,21) yet a consistent feature of invasive squa-”
BackgroundCharfi, L., Jouffroy, T., de Crémoux, P., Peltier, N. L., Thioux, M., Fréneaux, P., Point, D., Girod, A., Rodriguez, J., & Sastre‐Garau, X. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.10.028 · Cited by 74
“An up-regulation of the tumor suppressor protein p16 is a consequence of the inactivation of Rb [30].”
BackgroundA double dealing tale of p63: an oncogene or a tumor suppressor
Chen, Y., Peng, Y., Fan, S., Li, Y., Xiao, Z. J., & Li, C. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2666-y · Cited by 84
TEL-AML1 translocations with TEL and CDKN2 inactivation in acute lymphoblastic leukemia cell lines
Kim, D., Moldwin, R., Vignon, C., Bohlander, S., Suto, Y., Giordano, L., Gupta, R., Fears, S., Nucifora, G., & Rowley, J. (1996) · Blood · doi:10.1182/blood.v88.3.785.785 · Cited by 74
BANDYOPADHYAY, D., & MEDRANO, E. E. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06637.x · Cited by 73
Caco-2 intestinal cell differentiation is associated with G1 arrest and suppression of CDK2 and CDK4
Ding, Q.-M., Ko, T. C., & Evers, B. M. (1998) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1998.275.5.c1193 · Cited by 82
“Progression through early to mid-G1 is dependent on CDK4, and possibly CDK6, which are activated by association with one of the three D-type cyclins (D1, D2, and D3) (40).”
BackgroundWang, W., Wu, J., Zhang, Z., & Tong, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108278200 · Cited by 66
Chapeau, E. A., Gembarska, A., Durand, E. Y., Mandon, E., Estadieu, C., Romanet, V., Wiesmann, M., Tiedt, R., Lehar, J., de Weck, A., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620262114 · Cited by 64
“The latter gene encodes two tumor suppressor proteins: p16INK4a (3), an inhibitor of cyclin D-dependent kinases that, at least in part, regulates the function of the retinoblastoma protein (RB), and p19ARF (4), a negative regulator of double minute 2 protein (MDM2) function that activates TP53, thereby inducing cell c…”
BackgroundLelliott, E. J., McArthur, G. A., Oliaro, J., & Sheppard, K. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661737 · Cited by 65
Mart�n, J., Usac, E. F., Franco, C., Barbacid, M., Gomis, R., Marzo, N., Mora, C., & Fabregat, M. E. (2004) · Diabetologia · doi:10.1007/s00125-004-1372-0 · Cited by 65
“INK4 inhibitors associate with Cdk4 monomers in vivo [ 21 ] and prevent cyclin D1 binding to Cdk4, causing cell cycle arrest.”
BackgroundThe Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer
Kimura, H., Klein, A. P., Hruban, R. H., & Roberts, N. J. (2021) · Pancreas · doi:10.1097/mpa.0000000000001888 · Cited by 65
Wallis, R., Milligan, D., Hughes, B., Mizen, H., López-Domínguez, J. A., Eduputa, U., Tyler, E. J., Serrano, M., & Bishop, C. L. (2022) · Aging · doi:10.18632/aging.204072 · Cited by 58
Self-citation
Metadata
- Authors
- Serrano, M., Hannon, G. J., & Beach, D.
- Affiliations
- Howard Hughes Medical Institute (US)
- ORCID
- Hannon, Gregory J.
- Venue
- Nature
- Published
- 1993-12
- Volume
- 366
- Issue
- 6456
- Pages
- 704-707
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2066848701
- Cited by
- 3,650
- References
- 22
- Citations by year
- 2026: 36 · 2025: 46 · 2024: 52 · 2023: 66 · 2022: 67 · 2021: 78 · 2020: 64 · 2019: 63 · 2018: 56 · 2017: 70 · 2016: 69 · 2015: 75 · 2014: 52 · 2013: 98 · 2012: 88
- FWCI
- 78.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Keywords
- p16, CDK4, cyclin D, cyclin-dependent kinases, cell cycle regulation, G1 phase, kinase inhibition, retinoblastoma protein, p21, proliferating cell nuclear antigen, feedback regulation, cell proliferation
- MeSH terms
- Amino Acid Sequence, Base Sequence, Carrier Proteins, Cell Cycle, Cloning, Molecular, DNA, Glutathione Transferase, HeLa Cells, Humans, Molecular Sequence Data, Phosphorylation, Proto-Oncogene Proteins, Recombinant Fusion Proteins, Saccharomyces cerevisiae, Oncogene Proteins, Retinoblastoma Protein, Cyclins, Cyclin-Dependent Kinases, Cyclin D1, Cyclin-Dependent Kinase Inhibitor p16, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.